期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 72, 期 7, 页码 1136-1140出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-201861
关键词
-
类别
资金
- Actelion Pharmaceuticals US
- Scleroderma Research Foundation
- American College of Rheumatology Research and Education Foundation
- Arthritis Foundation
- NIH [P30 AR058885, 1K23AR052]
Objectives Annual echocardiography screening is widely used in scleroderma, but the utility of longitudinal assessment is unknown. We evaluated whether change in right ventricular systolic pressure (RVSP) was a risk factor for mortality and development of pulmonary arterial hypertension (PAH) in a cohort of scleroderma patients. Methods The study population consisted of scleroderma patients who had at least three echocardiograms and pulmonary function tests (PFTs) over >= 1 year as part of routine care. The annual rate of change in RVSP was determined for each subject. Cox proportional hazards regression was performed to assess the association between PAH and mortality and change in RVSP/year, adjusted for relevant covariates. Results 613 scleroderma patients with 3244 echocardiograms were studied. The adjusted relative hazards of PAH and mortality were 1.08 (95% CI 1.05-1.11) and 1.12 (95% CI 1.08-1.15) per 1 mm Hg increase in RVSP/year, respectively. Compared with patients with a stable RVSP, the relative hazards for the development of PAH were 1.90 (95% CI 0.91-3.96), 5.09 (95% CI 2.53-10.26) and 6.15 (95% CI 3.58-10.56) for subjects whose RVSP increased at rates of 1-1.99, 2-2.99 and 3+ mm Hg/year. Compared with the same reference group, the relative hazards for death were 0.92 (95% CI 0.48-1.73), 2.16 (95% CI 1.16-4.01) and 5.05 (95% CI 3.47-7.34) for subjects whose RVSP increased at rates of 1-1.99, 2-2.99 and 3+ mm Hg/year. Conclusions In a population of scleroderma patients, the rate of increase in RVSP is a risk factor for mortality and PAH even after adjustment for clinical characteristics and longitudinal PFT data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据